Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) Expected to Post Earnings of -$0.12 Per Share

Share on StockTwits

Equities analysts expect Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) to announce earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aerpio Pharmaceuticals’ earnings. Aerpio Pharmaceuticals reported earnings per share of ($0.21) in the same quarter last year, which would indicate a positive year-over-year growth rate of 42.9%. The company is expected to announce its next earnings report on Tuesday, March 3rd.

According to Zacks, analysts expect that Aerpio Pharmaceuticals will report full-year earnings of ($0.53) per share for the current year, with EPS estimates ranging from ($0.60) to ($0.46). For the next fiscal year, analysts expect that the company will post earnings of ($0.34) per share, with EPS estimates ranging from ($0.46) to ($0.21). Zacks’ earnings per share averages are an average based on a survey of analysts that cover Aerpio Pharmaceuticals.

NYSE ARPO traded down $0.03 during trading on Friday, hitting $0.56. The company had a trading volume of 168,904 shares, compared to its average volume of 250,169. The company’s fifty day moving average is $0.54 and its 200-day moving average is $0.73. Aerpio Pharmaceuticals has a one year low of $0.45 and a one year high of $4.25.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.

Further Reading: Current Ratio

Get a free copy of the Zacks research report on Aerpio Pharmaceuticals (ARPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Kiniksa Pharmaceuticals  Upgraded to Hold by Zacks Investment Research
Kiniksa Pharmaceuticals Upgraded to Hold by Zacks Investment Research
Newriver Reit  Price Target Cut to GBX 240
Newriver Reit Price Target Cut to GBX 240
Elementis  Rating Reiterated by UBS Group
Elementis Rating Reiterated by UBS Group
Victrex  Downgraded by UBS Group
Victrex Downgraded by UBS Group
Netcall’s  “Corporate” Rating Reiterated at FinnCap
Netcall’s “Corporate” Rating Reiterated at FinnCap
Hillenbrand  Rating Lowered to Sell at Zacks Investment Research
Hillenbrand Rating Lowered to Sell at Zacks Investment Research


© 2006-2020 Ticker Report